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Colonisation: establishment of bacteria in the upper respiratory tract without
causing overt disease.
Compartmentalisation: in the context of this article, the regional sequestration
of a specific function within the immune system. Local immune responses
within the body (site of infection) are often functionally independent from
systemic immunity.
Complement system: a cascade of plasma proteins that act together in defence
against extracellular bacteria by coating bacteria (opsonisation) or killing
pathogens directly.
Mucosal immunity: part of the immune system that is responsible for
protection against pathogens, commensals and other non-microbial antigens
restricted to the mucous membranes of the gastrointestinal, respiratory and
urinogenital tracts, i.e. the major sites of antigen/pathogen entry into the body.
Opsonisation: alteration of surfaces of pathogens by immune molecules in
such a manner that the pathogens are more easily recognised by immune cells.
Opsonophagocytosis: the process whereby bacteria are altered for optimal
interaction with phagocytes and then engulfed.Pneumococcal pneumonia is a life-threatening disease
with highmortality andmorbidity among children under
5 years of age, the elderly and immunocompromised
individuals worldwide. Protection against pneumococ-
cal pneumonia relies on successful regulation of coloni-
sation in the nasopharynx and a brisk alveolar
macrophage-mediated immune response in the lung.
Therefore, enhancing pulmonary mucosal immunity
(which includes a combination of innate, humoral and
cell-mediated immunity) through mucosal vaccination
might be the key to prevention of pneumococcal infec-
tion. Current challenges include a lack of information in
humans onmucosal immunity against pneumococci and
a lack of suitable adjuvants for new vaccines. Data from
mouse models, however, suggest that mucosally active
vaccines will enhance mucosal and systemic immunity
for protection against pneumococcal infection.
Prevention of pneumococcal pneumonia: current
strategies
Streptococcus pneumoniae (the pneumococcus) is a Gram-
positive aerobic commensal bacterium which forms part of
the normal flora in the nasopharynx [1]. The pneumococcus
can evade the immune system through a combination of
surface expressed and secreted virulence factors to cause
mucosal diseases such as otitis media, sinusitis and pneu-
monia, aswell as systemic diseases suchasbacteraemiaand
meningitis [1,2]. These diseases, collectively termed pneu-
mococcal disease, can be classified as invasive or non-inva-
sive disease. Otitis media, sinusitis and non-bacteraemic
pneumococcal pneumonia are examples of non-invasive
disease which are confined to the mucosal surface, whereas
bacteraemic pneumonia, bacteraemia and meningitis are
examples of invasive disease. Bacteraemic pneumococcal
pneumonia, defined as having pneumonia and a positive
blood culture [3], is more common in HIV-infected patients.
Invasive pneumococcal disease is thought to progress from
colonisation to bacteraemia, with or without pneumonia,
only a minority of cases developing meningitis (Figure 1).
Pneumonia accounts for 19% of all under 5 year old
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leading cause of pneumonia in children and it has been
reported to cause over 50% of severe pneumonia cases in
Africa [4]. Pneumococcal disease is most prevalent in the
young and the elderly, but is also very common among
HIV-infected individuals, who are 20–40 times more likely
than uninfected adults to suffer from this illness [5].
Pneumococcal pneumonia is treatable using antibiotic
therapy. However, where treatment is delayed or unavail-
able mortality is high [5]. Previously, the developing world
had focused on treating pneumococcal disease rather than
preventing it, but with the current increase in antibiotic
resistance and theHIV pandemic, it is widely accepted that
prevention is the key to minimising the disease burden [5].
Vaccination offers the most efficient and cost-effective
method of preventing this disease. However, there aremore
than 90 pneumococcal serotypes which make development
of a vaccine to provide universal protection a big challenge.
There are two formulations of pneumococcal vaccines that
have been licensed thus far: polysaccharide vaccines (PPVs)
and protein conjugate vaccines (PCVs). The 23-valent pneu-
mococcal polysaccharide vaccine, which contains purified
capsular polysaccharide antigens from 23 serotypes, offers
some protection against invasive pneumococcal disease in
adults but is not effective in either children less than 2 yearsSystemic immunity: the general immune system responsible for protection
against pathogens, commensals and other non-microbial antigens; it is not
confined to the site of infection or antigen entry.
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Figure 1. Diseases caused by Streptococcus pneumoniae. Pneumococci colonise the nasopharynx, evade host immunity and spread to the middle ear, sinus, lower
respiratory tract, blood and meninges. Pneumococci cause otitis media in the middle ear, sinusitis in the sinus, pneumonia in the lower respiratory tract, bacteraemia in
blood and meningitis in the meninges. The incidences of different types of pneumococcal infection are inversely related to the severity of disease: otitis media is the most
common but the least severe. Redrawn and redesigned with permission from Ref. [2].
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contain purified capsular polysaccharides conjugated to a
carrier protein, offer protectionagainstbothpneumoniaand
invasive disease in children [7] and immunocompromised
adults (French et al. unpublished). The currently licensed 7-
valent conjugate vaccine (containing 7 capsular polysac-
charides conjugated to a diphtheria CRM197 protein) is
being used as part of childhood immunisation programmes
in several countries but others are waiting for the licensing
of 10-valent and 13-valent vaccines. The disadvantages of
PCVs are that they are expensive, have limited serotype
coverage, can be associated with an increase in disease
caused by serotypes not included in the vaccine and are less
effective against radiological pneumonia (20–37% efficacy)
[7,8] than against invasive disease (77–83% efficacy) [7]. In
African children, PCVs appear to provide no protection to
unvaccinated children (herd immunity) and is not very
effective against colonisation (39% against vaccine sero-
types, 0% against all serotypes) [9].
There are several key developments that would result in
a breakthrough in the global control of pneumococcal dis-
ease. Use of the PCV is an important landmark [8] but the
use of conserved proteins in a universal vaccine would
allow a single vaccine to be deployed in all geographical
regions without regard to the prevalent serotype patterns.
In addition, the development of mucosally active vaccines
might reduce mucosal disease including pneumonia and82otitis media, but this will require the identification of safe
and effective mucosal adjuvants for successful vaccine
delivery.
This review will focus on recent advances in our un-
derstanding of mucosal immunity relevant to pneumococ-
cal infection and, in particular, the critical immune
responses that must be augmented by new vaccines.
Mucosal immunity against Streptococcus pneumonia
Host response against pneumococcal colonisation
Pneumococcal colonisation of the upper respiratory tract
precedes infection of the lower respiratory tract, but is
normally asymptomatic and not usually followed by dis-
ease [2]. The local host immune response plays an import-
ant role in regulating the containment of pathogens within
the nasopharyngeal cavity [2]. A brisk local host immune
response to S. pneumoniae involving phagocytes (neutro-
phils and macrophages), B cells (antibodies against pneu-
mococcal polysaccharides and proteins) and T cells rapidly
eliminates colonisation, whereas a poor mucosal immune
response results in protracted colonisation [2]. Both innate
and adaptive immunity play a role in these host defence
responses against S. pneumoniae.
Innate immune response during colonisation
Innate factors (including C-reactive protein, CRP) play a
crucial role in the host defence against colonisation with S.
Box 1. The role of pneumolysin in pneumonia and
bacteraemia
Pneumolysin is a potent pore-forming cytotoxin produced by almost
all pneumococcal isolates, and a proven virulence factor. Animal
studies show that this protein is required for the development of
pneumonia and bacteraemia. Data suggests that S. pneumoniae
requires pneumolysin to successfully survive in both the upper and
lower respiratory tracts [1,78,79]. The cytotoxin is essential for
pneumococcus to translocate from the lungs to the bloodstream
[1,78–80]. It is also required for bacterial survival in blood:
pneumolysin-expressing pneumococci are associated with high
bacteraemia and severe infection [79,80]. By contrast, pneumoly-
sin-deficient pneumococci result in low bacteraemia (often chronic)
with minimal severity in animal models [81].
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mainly found in serum and elevated during inflammation
[10]. It has also been detected in the upper respiratory tract
of healthy individuals and is also elevated during inflam-
mation [11]. The concentration of CRP is lower in the
respiratory tract than in serum but is sufficient to contrib-
ute to innate immunity, and is locally produced by epi-
thelial cells [11,12]. CRP has several functions in relation
to cell-surface phosphorylcholine-expressing bacteria
(such as S. pneumoniae and Haemophilus influenzae),
which includes activation of complement by the classical
pathway, enhancing opsonisation and inhibition of the
attachment of bacteria to epithelial cells [12]. These func-
tions help in clearance of colonising pneumococci from the
upper respiratory tract, which if not cleared might trans-
migrate across endothelial and epithelial monolayers in a
process called pericellular tissue invasion [13].
It is known that complement plays a role in protection
against pneumococcal infection through the promotion of
opsonophagocytosis [14,15]. However, there are still con-
flicting data on the role of complement in protection
against colonisation. Data from a co-colonisation mice
model (of S. pneumoniae and H. influenzae) suggest that
successful clearance of pneumococci in the nasopharynx
resulted from opsonisation by complement, followed by
phagocytosis by neutrophils which were recruited to the
mucosal surface [16]. In a different model, C3 (a protein
that plays a central role in activation of the complement
system) was essential within the lungs for an optimal
immune response against S. pneumoniae and sub-
sequently played an important role systemically [17]. In
contrast, another murine colonisation model showed that
C3-deficient mice lacking functional complement system
cleared pneumococcal colonisation at the same rate as wild
type mice [18]. It is important to take note that murine
models vary according to the genetic background of the
mouse and the serotype of pneumococcus used, and hence
they might not always produce similar results.
The innate response includes cellular responses from
neutrophils andmacrophages. It has been demonstrated in
murine models that pneumococcal colonisation of the
upper respiratory tract triggers an acute inflammatory
response characterised by a robust influx of neutrophils
into the lumen of the paranasal spaces [18,19] and release
of cytokines (tumour necrosis factor alpha, TNF-a) and
chemokines (interleukin 8, IL-8) [20]. This acute inflam-
matory response is ineffective at controlling initialmucosal
colonisation [19], but it enhances the adaptive immune
response and subsequent bacterial clearance [21].
Adaptive immune response during colonisation
Nasopharyngeal colonisation stimulates the production of
secretory IgA antibodies (the predominant immunoglobu-
lin class in human external secretions) and serum IgG [22].
However, it is unclear whether these antibodies are pro-
tective against colonisation. Many isolates of S. pneumo-
niae secrete a zinc metalloprotease which inactivates IgA1
(a subclass of IgA). Furthermore, the cleaved IgA1 frag-
ment might assist translocation of the opsonised bacteria
across the host respiratory epithelium [23]. By contrast,
increased concentrations of serotype-specific antibodiesagainst pneumococcal polysaccharides [24,25] and anti-
bodies against pneumococcal proteins in serum and saliva
[26] have been correlatedwith increased protection against
carriage. These antibodies opsonise pneumococci, making
it easier for phagocytes to recognise, ingest and clear
bacteria from the respiratory tract [27]. This has long been
thought to be the primary main mechanism for protection
against pneumococcal colonisation.
Several recent studies suggest that othermechanisms of
protection against pneumococcal carriage are required, in
addition to antibody-mediated immunity. Firstly, the
course of an experimental colonisation is not affected in
mice that are unable to produce pneumococcal-specific
antibody [28]. Secondly, the adaptive immune response
is enhanced in the presence of pneumolysin and neutro-
phils. Pneumolysin, a pore-forming cytotoxin is a critical
pathogenic factor ofS. pneumoniae (Box 1). The interaction
of pneumolysin and neutrophils promotes delivery and
release of pneumococcal-specific antigens to the nasal
associated lymphoid tissues, a process that is impaired
in either neutrophil- or pneumolysin-deficient conditions
[21]. Impaired antigen delivery is associated with pro-
longed nasopharyngeal colonisation [21]. Finally, mice
lacking the ability to induce a cell-mediated immunity
owing to the absence of appropriate molecules to present
antigens to CD4+ T cells (MHC-II knockout mice) show
prolonged carriage, suggesting an important role for CD4+
T cells rather than antibody-mediated immunity [29] (for
the antigen presentation process, see Figure 2).
Studies have shown that immunity to pneumococcal
colonisation is mediated by a specific subset of CD4+ T
cells (Th17) which produce IL-17A [30–34]. Malley et al.
showed that blocking IL-17A in mice models reduced
immunity to pneumococcal colonisation following intrana-
sal immunisation with cell wall polysaccharide [33]. In
another study by the same group, they showed that IL-
17A expression in peripheral blood samples from immu-
nised mice was associated with protection in vivo against
pneumococcal carriage [32].
IL-17A-mediated protection against pneumococcal colo-
nisation results in recruitment of neutrophils into the
upper airway lumen to clear bacterium [32,34]. Recently,
Zhang et al. showed that primary challenge with pneumo-
cocci in mice generates CD4+ T cell memory, resulting in
enhanced Th17-mediated recruitment of neutrophils after
secondary pneumococcal challenge [34]. These neutrophils
were shown to contribute to early bacterial clearance83
Figure 2. Induction of cell-mediated immune response by CD4+ T cells. There are three signals that are important during T cell activation: antigen presentation
(TCR:Peptide-MHC class II ligation), co-stimulation (CD40:CD40L and CD80/CD86:CD28) and polarising signals (cytokine milieu). Professional antigen-presenting cells
(dendritic cells, B cells and macrophages) present antigens to T cells in the context of MHC class II via the TCR (T cell receptor). This induces upregulation of CD40L and
CD28 on the T cells, which bind to their receptors CD40 and CD80/CD86, respectively, on APCs, in a process called co-stimulation. These events lead to the production of
polarising cytokines by APCs which include IL-12 from macrophages and dendritic cells, and IL-23 from dendritic cells. The polarising cytokines are important because they
dictate the fate of T cells on whether to differentiate into Th1, Th2 or Th17.
Review Trends in Microbiology Vol.18 No.2following secondary challenge [34]. However, it is still not
clear whether Th17 cells are involved in immunity against
human pneumococcal colonisation.
Host response against pneumococcal pneumonia
Post colonisation events leading to pneumonia
If pneumococci colonising the human nasopharynx are
aspirated into the distal airways and alveolar air spaces,
they will interact with pulmonary defence mechanisms.
The bacteria will either be cleared or cause disease. Exces-
sive replication of the bacteria in the alveoli triggers
infiltration of immune cells which – if not properly
regulated – impairs gas exchange resulting in the clinical
syndrome of pneumonia.
The process of bacterial clearance in the lung is a highly
regulated process – an excessive responsemight potentially
lead to tissue damage, whereas a weak response leads to
exponential growth of the pathogens. The primary host
immune defence against small numbers of pneumococci
duringearly infection isphagocytosis [27]which is enhanced
through opsonisation by immunoglobulin and complement
[19], inaprocess calledopsonophagocytosis.Themechanism
of host defence against pneumococci during late infection is
different. It involves multiple immune cells and combi-
nation of innate and adaptive immunity.
Early infection in the lung
Alveolar macrophages are the first cells that combat pneu-
mococci during early infection [35] and the main cell84population that mediates mucosal responses in the lower
airways [36,37]. Approximately 90% of cells found in
bronchoalveolar lavage fluid of healthy volunteers are
macrophages [37]. It has been suggested that during early
infection (where the bacterial load is low), resident alveolar
macrophages are capable of multiple episodes of phagocy-
tosis and killing [38]. This helps to clear the bacteria
without recruitment of inflammatory cells such as neutro-
phils, and hence maintaining a low inflammatory state in
the lung [38]. Early clearance of pneumococci through
alveolar macrophage phagocytosis probably prevents bac-
teria–dendritic cell interaction, which in turn limits the
initiation of T cell-mediated inflammatory responses in the
lymph node [37].
It is still unclear whether antigen presentation occurs in
the lung, in the draining lymph nodes, or both, and
whether alveolar macrophages are part of this antigen
presentation process. There is data in vitro to suggest that
alveolar macrophages are able to present antigens to T
cells, although less effectively than other antigen-present-
ing cells (APCs) [39]. Alveolar macrophages might induce
antigen-specific unresponsiveness in CD4+ T cells as a
result of antigen recognition in the absence of co-stimu-
lation [39] (for the antigen presentation process, see
Figure 2).
Late infection in the lung
When the alveolar bacterial load rises above a critical
threshold, alveolar macrophages cease to perform effective
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matory cytokine response dominated by TNF-a and IL-8
[38]. The presence of TNF-a is not a prerequisite for
pulmonary anti-pneumococcal responses, because success-
ful clearance of the bacteria can occur independent of this
cytokine – but it is beneficial during systemic infection [40].
Inflamed epithelial cells enhance neutrophil recruitment
into the lung by secretion of IL-8 [41], both as a direct result
of pneumococcal binding to epithelial receptors and in
response to macrophage proinflammatory signalling.
When a proinflammatory signal (TNF-a and/or IL-8) is
produced in the alveolus, there is upregulation of adher-
ence molecules on endothelial cells which bind to their
receptors on neutrophils. This results in rolling of neutro-
phils along the endothelial wall and transmigration into
the alveolar space in a process called chemotaxis [42].
Neutrophils then become the major immune cell popu-
lation responsible for pneumococcal clearance in the lung
[43].Figure 3. Pneumococcal clearance in the lung. Host defence in the lower respiratory trac
load is low, resident alveolar macrophages efficiently kill and phagocytise opsonised
interaction, and hence inhibiting initiation of T cell-mediated inflammatory responses
perform effective opsonophagocytosis, neutrophils are recruited following secretion
recruited following successful antigen presentation in the draining lymph nodes by pulm
internalised pneumococci and also promotes further TNF-a production by alveolar ma
some macrophages and T cells undergo rapid apoptosis. Surviving T cells remain in thT cells are also recruited in high numbers to the lung in
late infection – the peak of T cell infiltration in the lung
during intranasal pneumococcal infection in mice in vivo
coincided with the phase when bacterial growth ceased
[44]. The recruited T cells are predominantly of the effector
memory phenotype and potentially secrete interferon
gamma IFN-g to activate alveolar macrophages. The
actual mechanisms on the role played by T cells are still
not clear, but we have hypothesised some of the possible
pathways in Figure 3. In addition, it has been shown that T
cells expressing the gammadelta receptor (gd T cells) act as
regulators of alveolar macrophages and pulmonary den-
dritic cells during the resolution of pneumococcus-
mediated lung inflammation [45]. Cytoxicity mediated
by gd T cells helps restore mononuclear phagocyte num-
bers to homeostatic levels, and hence preventing excessive
inflammation in the lung [45].
Following clearance of pneumococci from the lungs,
neutrophils, some macrophages and T cells undergo rapidt is mediated by alveolar macrophages. (i) During early infection where the bacterial
pneumococci in a quiescent manner, effectively preventing bacteria–dendritic cell
. (ii) In situations where bacterial load exceeds the capability for macrophages to
of TNF-a by alveolar macrophages and/or IL-8 by epithelial cells. (iii) T cells are
onary dendritic cells. These cells secrete IFN-g which activates macrophages to kill
crophages. (iv) Following clearance of pneumococci from the lungs, neutrophils,
e alveoli as resident effector memory cells.
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expression, which in turn results in reduced neutrophil
recruitment and enhanced neutrophil apoptosis [46]. Dead
cells are then cleared through phagocytosis, efferocytosis
(clearance of apoptotic cells by phagocytes) and the normal
function of the mucociliary escalator, whereas the surviv-
ing T cells remain in the alveoli as resident effector mem-
ory cells.
In summary, mucosal responses are critical in regulat-
ing pneumococcal carriage and defence against infection.
Therefore, enhancing pulmonary mucosal immunity might
be an effective strategy in the prevention of pneumococcal
disease.
Evidence for vaccine-induced mucosal immunity
against pneumococcus
Mucosal exposure to S. pneumoniae induces both mucosal
and systemic humoral and cellular immune responses
[25,26]. Enhancing these responses bymucosal vaccination
is an attractive immunisation approach against pneumo-
coccus as it mimics the natural route of infection. The
success of other mucosal vaccines such as the trivalent
oral poliovirus vaccine shows that this approach is a viable
alternative of delivering vaccines [47]. There is evidence
from mouse models, employing a similar route of vaccine
delivery, showing that oral immunisation of PspA family
fusion proteins delivered by attenuated Salmonella enter-
ica serovar Typhimurium enhances protection against S.
pneumoniae [48–51]. An important difference is that polio
virus can replicate in the respiratory mucosa but pneumo-
coccal antigens cannot. Nevertheless, there are several
studies which have shown that mucosal immunisation
can elicit protection against pneumococcal colonisation
and infection (Table 1).
Protection against pneumococcal colonisation
Mucosal immunisation of experimental animals has been
shown to elicit protection against carriage [29,52]. Intra-
nasal immunisation of mice with killed, unencapsulated,Table 1. Mouse models of mucosal immunisation with pneumoco
Antigen or vaccine Route Immunogenicity Correlates
PspA Intranasal Mucosal and systemic Antibodies
PspA/attenuated
Salmonella
Oral Mucosal and systemic Antibodies
vaginal flui
PsaA Oral Mucosal and systemic Antibodies
intestinal fl
PsaA/lactic acid
bacteria
Intranasal Mucosal and systemic Antibodies
nasal and b
PotD Intranasal Mucosal and systemic Antibodies
PsaA and PspA Intranasal Mucosal and systemic Antibodies
PspA and PspC Intranasal Mucosal and systemic Antibodies
washes, an
responses
lung and sp
PsaA, PdT and
CWPS
Intranasal Systemic Antibodies
response in
GEM with PpmA,
SlrA and IgA1p
Intranasal Systemic Antibodies
PCV Intranasal Mucosal and systemic Antibodies
nasal wash
aAbbreviations: PspA, pneumococcal surface protein A; PsaA, ‘pneumococcal surface adh
PspC, pneumococcal surface protein C; PdT, pneumolysin nontoxic derivative; CWPS, c
conjugate vaccine.
86whole cell pneumococci and cholera toxin adjuvant elicited
protection against experimental colonisation. The protec-
tion was dependent on CD4+ T cells and independent of
antibody and bacterial serotype [29]. Furthermore, intra-
nasal immunisation with a cholera toxin B subunit fused to
the pneumococcal surface adhesin A (PsaA) also protected
mice against colonisation with S. pneumoniae [52].
An ideal mucosal vaccine would include several pneu-
mococcal proteins such as pneumolysin, PspA, PsaA or
PspC [53]. Many of these proteins play a role in S. pneu-
moniae pathogenesis, and several are particularly relevant
to protection against carriage [54]. Recently, Lu et al.
demonstrated that a fusion conjugate, including cell wall
polysaccharide coupled to pneumolysin and PsaA, deliv-
ered intranasally with cholera toxin, protected mice
against experimental pneumococcal colonisation [31].
Mucosal vaccines based on protein combinations are more
likely to exhibit coverage of all pneumococcal serotypes.
Protection against pneumococcal pneumonia
Pneumococcal conjugate vaccine is less effective against
pneumonia than against invasive pneumococcal disease
[7,8]. This observation might be as a result of difficulty
either in the diagnosis of non-bacteraemic pneumococcal
pneumonia or in distinguishing this diagnosis from other
infective causes of pneumonia. Consequently, the chances
of underreporting non-bacteraemic pneumococcal pneumo-
nia as an endpoint in determining efficacy of the pneumo-
coccal conjugate vaccine are high. By contrast, the
intramuscular administration of the vaccine might result
in a compartmentalisation of the immune response and a
suboptimal lymphocyte trafficking to the pulmonary
mucosa.
Mucosal vaccination has shown promising results in
protection against pneumococcal lung infection [31,55–
57]. Nasal administration of Lactococcus lactis increased
the clearance rate of S. pneumoniae from the lung and
prevented invasion of pneumococci into blood [57]. In these
experiments, L. lactis increased phagocyte activation inccal protein antigensa
of protection Protection against: Refs
in serum and saliva Colonisation, pneumonia, sepsis [60–62]
in serum and
ds
Pneumonia, bacteraemia [48–51,63]
in serum, BAL and
uid
Pneumonia, bacteraemia [52,64,65]
in serum, saliva,
ronchial washes
Colonisation [66]
in serum and saliva Colonisation, pneumonia,
bacteraemia
[67]
in serum and saliva Colonisation [68]
in serum, vaginal
d BAL; cytokine
in BAL,
lenic samples
Pneumonia, bacteraemia [69,70]
in serum; T cell
whole blood
Colonisation, pneumonia [31,71]
in serum Pneumonia [72,73]
in serum and
es
Colonisation, otitis media [74–77]
esion A’ protein; BAL, bronchoalveolar lavage; PotD, polyamine transport protein D;
ell wall polysaccharide; GEM, Gram-positive enhancer matrix; PCV, pneumococcal
Review Trends in Microbiology Vol.18 No.2lung, blood and bone marrow of the vaccinated mice [57].
Moreover, mucosal immunisation with caseinolytic pro-
tease, a conserved pneumococcal protein, induced the pro-
duction of both systemic and mucosal antibodies and
resulted in reduced lung bacterial load in a pneumococcal
pneumonia model and prevented death in an intraperito-
neal sepsis model [58]. Lastly, a mucosal vaccine made of
recombinant PspA elicited protection against invasive
pneumococcal challenge, characterised by increased
secretion of IL-17 and IFN-g by lung and spleen cells,
respectively [55]. These data support the concept that
mucosal immunisation might protect against both mucosal
and systemic infection. However, the duration of protection
afforded by these mucosal vaccines is not clear.
There are also some data to suggest that mucosally
administered vaccines might actually provide better pro-
tection against both mucosal and systemic disease than
conventional parenteral (systemic) vaccines. Immunis-
ation of mice with lactococcal PspA vaccine elicited better
protection against respiratory pneumococcal challenge
than conventional parenteral PspA vaccine in intraperito-
neal sepsis and intranasal respiratory infection models
[56].
In summary, there are encouraging data to support the
role of mucosal vaccination in protection against both
mucosal and systemic pneumococcal disease. However,
lack of a suitable adjuvant is a major obstacle to success,
but cytokine adjuvants might be useful [59].
Concluding remarks and future directions
We have discussed the role of mucosal immunity and
reviewed available data on mucosal immunisation against
pneumococcal disease. There is evidence from murine
studies to suggest that mucosal immunisation against
pneumococci induces mucosal and systemic immunity
more effectively than parenteral vaccination. The data
from humans, however, are insufficient to draw firm con-
clusions. Further studies using lung, nasal and other
mucosal samples from humans are needed.
Immediate priorities include the need to address the role
of T cell-mediated immunity against pneumococcal coloni-
sation and infection in humans. Such datamight clarify the
human correlates of protection or immunity to S. pneumo-
niae. These correlates of protection might then help in
predicting efficacy to future vaccines. Research questions
for future work in the field are outlined in Box 2.
Strategic decisions regarding future pneumococcal
vaccines need to determine whether to focus on improving
the current conjugate vaccines (by including more sero-Box 2. Questions for future research
 What are the correlates of protection (measurable signs of
immunity) against carriage and disease as a result of S.
pneumoniae in human mucosa?
 Which is the most effective mode of vaccine delivery to enhance
both mucosal and systemic immunity to S. pneumoniae?
 What adjuvants are most effective for mucosal pneumococcal
vaccine delivery?
 How does HIV infection affect mucosal immunity against S.
pneumoniae in the respiratory tract?types or replacing the carrier with a pneumococcal
protein) or developing new pneumococcal protein based
vaccines. Pneumococcal conjugate vaccines are currently
being used in several developed countries because they
provide good protection against systemic disease. Their
main disadvantage is that they have limited serotype
coverage and are less effective against mucosal disease.
By contrast, pneumococcal protein based vaccines have
the potential to offer universal coverage as well as offer
protection against both mucosal and systemic disease if
delivered through the mucosal route. Vaccination still
remains the key to minimising the high burden of pneu-
mococcal disease worldwide. We believe that alternative
routes of immunisation (with conjugate vaccines or pneu-
mococcal proteins) might help in improving the efficacy of
pneumococcal vaccines to both mucosal and systemic
disease.
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